Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NxStage Medical Resource Report Resource Website 1+ mentions |
NxStage Medical (RRID:SCR_004000) | NXTM, NxStage | commercial organization | A medical device company that develops, manufactures and markets innovative dialysis systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. | medical device, kidney, dialysis, hemodialysis, home hemodialysis | is related to: Kidney Health Initiative | End-stage renal disease, Acute kidney failure | nlx_158411 | SCR_004000 | NxStage Medical Inc, NxStage Medical Inc. | 2026-02-14 02:00:39 | 1 | |||||||
|
Almirall Resource Report Resource Website 1+ mentions |
Almirall (RRID:SCR_003947) | Almirall | commercial organization | A pharmaceutical company committed to provide valuable medicines through their own R&D efforts, licenses and collaborations. Through seeking innovative medicines they aim to become a relevant player in respiratory and dermatology diseases with also a strong interest in gastroenterology and pain. The company is headquartered in Barcelona, Spain, and has 14 affiliates in Europe and North America and trading capacity in 22 countries. | gastroenterology, respiratory, dermatology, pharmaceutical, medicine, drug | is related to: Open PHACTS | Respiratory disease, Dermatologic disease, Pain, Gastrointestinal disease, Gastrointestinal condition | nlx_158340 | SCR_003947 | S.A., Laboratories Almirall S.A., Almirall | 2026-02-14 02:00:38 | 4 | |||||||
|
American Society of Transplantation Resource Report Resource Website 1+ mentions |
American Society of Transplantation (RRID:SCR_003970) | AST | professional organization | An organization of transplant professionals dedicated to advancing the field of transplantation and improving patient care by promoting research, education, advocacy, and organ donation. | transplantation, patient care, organ donation, organ, training resource | is related to: Kidney Health Initiative | nlx_158377, Wikidata: Q4745115, Crossref funder ID: 100005160, ISNI: 0000 0001 0409 3433, grid.461608.d | https://ror.org/05cqqj259 | SCR_003970 | 2026-02-14 02:00:53 | 4 | ||||||||
|
Arbor Research Collaborative for Health Resource Report Resource Website 1+ mentions |
Arbor Research Collaborative for Health (RRID:SCR_003972) | Arbor Research | nonprofit organization | A not-for-profit research organization committed to improve patient care through research that shapes medical policies and practice. In particular, they conduct health outcomes research on chronic disease and end-stage organ failure, with expertise in biostatistical analysis, clinical practice, health economics, public policy, database management and integration, and project coordination. Through research projects that are national and global in scope, their scientific collaborations provide valuable and timely information to the worldwide health care community. They are a leader in interdisciplinary health outcomes and policy research focused on reducing the health and economic burden of chronic diseases and improving the delivery of care. | health outcome, patient care, clinical, policy, nephrology, statistics, kidney, transplant, dialysis, epidemiology, public health, clinical practice, policy development, medical payment system | is related to: Kidney Health Initiative | Kidney disease, Organ failure, Chronic disease | grid.413857.c, nlx_158379, ISNI: 0000 0004 0628 9837 | https://ror.org/043qmbk61 | SCR_003972 | URREA, University Renal Research and Education Association | 2026-02-14 02:00:55 | 3 | ||||||
|
American Nephrology Nurses Association Resource Report Resource Website 1+ mentions |
American Nephrology Nurses Association (RRID:SCR_003966) | ANNA | institution | Non-profit professional association that represents nurses who work in all areas of nephrology including hemodialysis, chronic kidney disease, peritoneal dialysis, acute care, and transplantation. Most members work in freestanding dialysis units, hospital outpatient units, and hospital inpatient units. ANNA develops and updates standards of clinical practice, educates practitioners, stimulates and supports research, disseminates knowledge and new ideas, promotes interdisciplinary communication and cooperation, and monitors and addresses issues encompassing the breadth of practice of nephrology nursing. | clinical, kidney, nephrology, nurse, health care, dialysis, journal, training resource |
is related to: Nephrology Nursing Certification Commission is related to: Kidney Health Initiative |
Kidney disease | grid.469735.a, nlx_158371, ISNI: 0000 0000 9310 7210, Crossref funder ID: 100005526 | https://ror.org/05a8c4g41 | SCR_003966 | American Nephrology Nurses'' Association | 2026-02-14 02:00:53 | 1 | ||||||
|
Experimental Pharmacology and Oncology Berlin-Buch Resource Report Resource Website 1+ mentions |
Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR_003954) | EPO | commercial organization | A small and medium-sized enterprise (SME) that has expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and predictive biomarkers like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO has modern laboratories licensed for animal experiments and gene technology (S2) and a broad panel of murine and human tumor models growing in immunocompetent (SPF-quality, syngeneic strains) or immunodeficient mice (nude, SCID, NOD/SCID). EPO has established imaging technologies to monitor in vivo tumor growth. | tumor model, pharmaceutical, oncology, in vitro, in vivo, antitumor, preclinical, pharmacology, pharmacokinetics, toxicology, anticancer, therapeutic, biomarker, imaging, testing, validation, target | is related to: OncoTrack | Tumor, Cancer | nlx_158355 | SCR_003954 | EPO - Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology Berlin-Buch, Experimental Pharmacology & Oncology Berlin-Buch GmbH, EPO Berlin-Buch GmbH, EPO-GmbH | 2026-02-14 02:00:53 | 2 | |||||||
|
Alacris Theranostics Resource Report Resource Website |
Alacris Theranostics (RRID:SCR_003953) | Alacris | commercial organization | Commercial organization that uses next generation sequencing technologies coupled with computational modeling of tumor and somatic tissues in order to identify individualized therapies for cancer patients. The company also uses these technologies to help pharmaceutical partners stratify patients for their clinical trials. Alacris has an exclusive worldwide commercial license for the computational modeling of tumors and somatic tissues using proprietary computational systems modeling technologies ModCell developed at the Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin coupled with next generation sequencing and genotyping technology developed at Harvard Medical School in Boston. The company also is building up the first next generation sequencing center in Europe for clinical operations. | next generation sequencing, computational modeling, clinical trial, somatic tissue, genotyping, genomics, oncogenomics, diagnostics, therapy, disease model, drug, personalized medicine, biomarker, drug development, tumor model, analysis, oncology | is related to: OncoTrack | Tumor, Cancer | nlx_158354, grid.473915.d | https://ror.org/04a0gnr15 | SCR_003953 | Alacris Theranostics GmbH | 2026-02-14 02:00:34 | 0 | ||||||
|
Vasculitis Foundation Resource Report Resource Website |
Vasculitis Foundation (RRID:SCR_004059) | VF | institution | An international organization for patients with vasculitis, their families, friends and the health care professionals who care for them, supporting and empowering them through education, awareness and research. The Foundation advocates for early diagnosis and leading edge treatment for all. The Foundation also partners with researchers around the world to determine the cause and discover the cure for vasculitis. | clinical, pediatric, child, funding resource | is related to: Kidney Health Initiative | Vasculitis | Crossref funder ID: 100007211, grid.453926.f, nlx_158493 | https://ror.org/03f9wqe45 | SCR_004059 | 2026-02-14 02:00:36 | 0 | |||||||
|
Biomol-Informatics Resource Report Resource Website 1+ mentions |
Biomol-Informatics (RRID:SCR_004081) | commercial organization | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 12, 2021. Technology based company in Madrid that offers consulting services on Bioinformatics in areas of research, diagnostics and pharmaceutical industry. | bioinformatics, genome sequencing, genome, sequencing, exome, protein-protein interaction, analysis, molecular dynamics, 3d modeling, evolutive information, training service resource, next generation sequencing, simulation, drug design, computational simulation, macromolecule, molecular dynamics, quantum mechanics, molecular mechanics, dna, protein |
is related to: European Gram Negative AntiBacterial Engine has parent organization: Autonomous University of Madrid; Madrid; Spain |
THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158539, grid.432020.7, Wikidata Q30254873 | https://ror.org/057rd1163 | SCR_004081 | Biomol-Informatics SL | 2026-02-14 02:00:56 | 3 | |||||||
|
Hoosier Cancer Research Network Resource Report Resource Website |
Hoosier Cancer Research Network (RRID:SCR_004026) | HCRN | nonprofit organization | An independent nonprofit cancer research organization that provides full-service clinical trial management and support, from conception and study design through project completion and publication. Established to explore and develop leading edge cancer treatments across the United States and internationally, their clinical trials, developed in collaboration with academic and community oncologists, are conducted within a member network of more than 130 clinical research sites. Their vision and mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech partners with the goal of advancing cancer research, education, and patient advocacy. There are no costs to become a member. | oncology, clinical trial, clinical | is parent organization of: Big Ten Cancer Research Consortium | Cancer | nlx_158453, Wikidata: Q30287333, grid.428706.f | https://ror.org/02mtpb511 | SCR_004026 | Hoosier Oncology Group | 2026-02-14 02:00:55 | 0 | ||||||
|
BARI 2D Resource Report Resource Website 1+ mentions |
BARI 2D (RRID:SCR_001496) | BARI 2D, BARI-2D | clinical trial | A multicenter randomized clinical trial that aims to determine the best therapies for people with type 2 diabetes and moderately severe cardiovascular disease. 2368 participants were randomized at 49 sites in 6 countries. All subjects were given intensive medical therapy to control cholesterol and blood pressure and given counseling, if needed, to quit smoking and to lose weight. Beyond that, they compared whether prompt revascularization, either bypass surgery or angioplasty, e.g. stents, was more effective than medical therapy alone. At the same time, they also looked at which of two diabetes treatment strategies resulted in better outcomes����??insulin-providing versus insulin-sensitizing - that is, increasing the amount of insulin or making the insulin work better. Only patients with known type 2 diabetes and heart disease that could be treated appropriately with a revascularization OR medical therapy alone were eligible for the trial. Patients entered the study between January 2001 ����?? March 2005 and were followed for an average of five years. When a patient entered the study, physicians first decided whether that patient should receive stenting or bypass surgery. The patient then received their randomization assignment. All patients were treated in BARI 2D for both their diabetes and heart disease, as well as other risk factors that might effect those diseases, regardless of which group they were in. Diabetes-specific complications including retinopathy, nephropathy, neuropathy, and peripheral vascular disease were monitored regularly. Tests, blood samples, urine samples, and treatment cost data were obtained periodically through the trial and examined by experts at 7 central laboratories and other research partners. Experts on risk factors routinely oversaw treatments of all patients at 4 central management centers. A panel of independent experts reviewed data every six months to make sure that all patients were receiving safe care. | clinical, cholesterol, blood pressure, counseling, insulin, epidemiology, longitudinal, stenting, bypass surgery, standard-of-care study, standard-of-care, treatment, medication, outcome, medical cost, blood, urine, biomaterial supply resource |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pittsburgh; Pennsylvania; USA |
Type 2 diabetes, Cardiovascular disease, Heart attack, Stroke | NCRR 5M01RR000847-36 | PMID:23757426 PMID:23735723 PMID:23500245 PMID:23067918 PMID:23008442 PMID:22527794 PMID:22496082 PMID:21958742 |
Free, Freely available | nlx_152754 | SCR_001496 | Bypass Angioplasty Revascularization Investigation (BARI) 2 Diabetes, Bypass Angioplasty Revascularization Investigation 2 Diabetes | 2026-02-14 02:00:04 | 1 | ||||
|
Juvenile Diabetes Research Foundation Resource Report Resource Website 50+ mentions |
Juvenile Diabetes Research Foundation (RRID:SCR_001522) | JDRF | institution | Global funder of type 1 diabetes (T1D) research that aims to progressively remove the impact of T1D from people's lives until a world without T1D is achieved. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness. The organization awards research grants for laboratory and clinical investigations and sponsors a variety of career development and research training programs for new and established investigators. JDRF also sponsors international workshops and conferences for biomedical researchers. Individual chapters offer support groups and other activities for families affected by diabetes. | treatment, prevention, cure, research, education |
is listed by: NIDDK Information Network (dkNET) is affiliated with: Helmsley Cellular Research Hub is related to: JDRF Artificial Pancreas Project Consortium is related to: Kidney Health Initiative |
Type 1 diaberes, Diabetes | Free, Freely available | grid.429307.b, nlx_152841, Crossref funder ID: 100008871, Wikidata: Q6107958, ISNI: 0000 0004 0575 6413 | https://ror.org/00vqxjy61 | SCR_001522 | JDRF International, Juvenile Diabetes Research Foundation International | 2026-02-14 02:00:04 | 64 | |||||
|
Multiple-Path Particle Dosimetry Model Resource Report Resource Website 10+ mentions |
Multiple-Path Particle Dosimetry Model (RRID:SCR_001486) | MPPD | software resource | Computational model that can be used for estimating human and rat airway particle dosimetry. The model is applicable to risk assessment, research, and education. The MPPD model calculates the deposition and clearance of monodisperse and polydisperse aerosols in the respiratory tracts of rats and human adults and children (deposition only) for particles ranging in size from ultrafine (0.01 micrometers) to coarse (20 micrometers). The models are based on single-path and multiple-path methods for tracking air flow and calculating aerosol deposition in the lung. The single-path method calculates deposition in a typical path per airway generation, while the multiple-path method calculates particle deposition in all airways of the lung and provides lobar-specific and airway-specific information. Within each airway, deposition is calculated using theoretically derived efficiencies for deposition by diffusion, sedimentation, and impaction within the airway or airway bifurcation. Filtration of aerosols by the nose and mouth is determined using empirical efficiency functions. The MPPD model includes calculations of particle clearance in the lung following deposition. | model, computational model, particle dosimetry, risk assessment, adult human, child, aerosol, deposition, clearance, lung | is related to: The Hamner Institute for Health Sciences: BMDExpress and The multiple-path particle dosimetry | PMID:8566482 | Free, Freely available | nlx_152744 | http://www.ara.com/products/mppd.htm | SCR_001486 | Multiple Path Particle Dosimetry Model | 2026-02-14 02:00:01 | 11 | |||||
|
Jaeb Center for Health Research Resource Report Resource Website 1+ mentions |
Jaeb Center for Health Research (RRID:SCR_001513) | JCHR | institution | Freestanding, nonprofit coordinating center for multi-center clinical trials and epidemiologic research that focus on projects involving eye disorders or type 1 diabetes. | epidemiologic research, epidemiology, clinical, disease, clinical trial, eye |
is parent organization of: Diabetes Research in Children Network is parent organization of: Diabetic Retinopathy Clinical Research Network is parent organization of: JDRF Artificial Pancreas Project Consortium |
Type 1 diabetes, Multiple sclerosis, Eye disorder, Diabetes | Free, Freely available | ISNI: 0000 0004 0586 473X, nlx_152815, grid.414912.b | https://ror.org/04ezjnq35 | SCR_001513 | 2026-02-14 02:00:05 | 4 | ||||||
|
TRIGR Resource Report Resource Website 1+ mentions |
TRIGR (RRID:SCR_001550) | TRIGR | clinical trial | International, randomized, double-blinded trial to determine whether weaning to a casein hydrolysate formula during the first 6-8 months of life in place of cow milk based formula reduces the incidence of autoimmunity and type 1 diabetes in genetically susceptible newborn infants. 2160 eligible infants were randomized to test or control formulas when mothers decide to wean from exclusive breastfeeding. The participants will be monitored up to the age of 10 years for the appearance of diabetes-predictive autoantibodies and clinical type 1 diabetes. The TRIGR trial will determine whether delayed exposure to intact food proteins will reduce the chances of developing type 1 diabetes later in life. All babies in the study received the recommendation to breastfeed for at least the first six months of life. If a mother was unable to exclusively breastfeed before the baby was 8 months of age, her child was randomly assigned to one of two groups. One group of these babies received a trial formula based on extensively hydrolyzed protein; the other group received another trial formula containing a smaller amount of hydrolyzed protein. In the hydrolyzed formula, the big protein molecules have been split into very small fragments to provide a source of nutritional amino acids, but the fragments are likely too small to stimulate the immune system. The TRIGR trial will also be able to analyze whether exclusive breastfeeding per se can reduce the risk of the children to develop type 1 diabetes. | casein hydrolysate formula, newborn, hydrolyzed infant formula, genetically susceptible, insulin, cow's milk, infant, feeding, diet, intervention, genetic risk, bibliography, dietary intervention, wean, prevention, nutrition, nonhydrolyzed infant formula, breast feeding, infant formula |
is listed by: ClinicalTrials.gov is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) has parent organization: University of South Florida; Florida; USA |
Type 1 diabetes, Diabetes | NICHD HD040364; NICHD HD042444; NICHD HD051997; RTD programme Quality of Life and Management of Living Resources contract QLK1-2002-00372 |
PMID:21153533 PMID:17550422 |
Free, Freely available | nlx_152860 | http://trigr.epi.usf.edu/ http://clinicaltrials.gov/show/NCT00179777 |
SCR_001550 | TRIGR - Trial to Reduce IDDM in the Genetically at Risk, Trial to Reduce IDDM in the Genetically at Risk, TRIGR trial | 2026-02-14 02:00:03 | 1 | |||
|
SNPper Resource Report Resource Website 10+ mentions |
SNPper (RRID:SCR_001963) | SNPper | software resource | Retrieve known single-nucleotide polymorphisms (SNPs) by position or by association with a gene; save, filter, analyze, display or export SNP sets; explore known genes using names or chromosome positions. | single-nucleotide polymorphism, gene, chromosome |
is listed by: OMICtools has parent organization: University of Florida; Florida; USA |
PMID:12490454 | THIS RESOURCE IS NO LONGER IN SERVICE | OMICS_01926 | SCR_001963 | 2026-02-14 02:00:21 | 49 | |||||||
|
Parkinson Society Canada Resource Report Resource Website 1+ mentions |
Parkinson Society Canada (RRID:SCR_002014) | nonprofit organization | A not-for-profit, volunteer based charity whose purpose is to find a cure for Parkinson's disease through research, advocacy, education and support services. Parkinson Society Canadas leads initiatives that include: raising funds for research through national events; funding research, movement disorder clinics, and outreach programs across Canada; staffing a national Information and Referral Centre; developing educational and information materials; providing up to date detailed information about Parkinson's disease; and providing support for regional partners to better meet the needs of people living with Parkinson's services. Researchers can apply for various funding awards and fellowships by following the funding process outlined by Parkinson Society Canada. | parkinson's disease, parkinson's disease online community, parkinson's disease organizations, parkinson's disease patient care, parkinson's disease therapy, parkinson's disease treatment center | Parkinson's Disease | Public, Funding is available to researchers in the form of awards and fellowships | grid.453461.1, Crossref funder ID: 501100000263, nif-0000-11672 | https://ror.org/04amfk357 | SCR_002014 | 2026-02-14 02:00:13 | 3 | ||||||||
|
Wellcome Trust Case Control Consortium Resource Report Resource Website 100+ mentions |
Wellcome Trust Case Control Consortium (RRID:SCR_001973) | WTCCC | data or information resource | Consortium of 50 research groups across the UK to harness the power of newly-available genotyping technologies to improve our understanding of the aetiological basis of several major causes of global disease. The consortium has gathered genotype data for up to 500,000 sites of genome sequence variation (single nucleotide polymorphisms or SNPs) in samples ascertained for the disease phenotypes. Analysis of the genome-wide association data generated has lead to the identification of many SNPs and genes showing evidence of association with disease susceptibility, some of which will be followed up in future studies. In addition, the Consortium has gained important insights into the technical, analytical, methodological and biological aspects of genome-wide association analysis. The core of the study comprised an analysis of 2,000 samples from each of seven diseases (type 1 diabetes, type 2 diabetes, coronary heart disease, hypertension, bipolar disorder, rheumatoid arthritis and Crohn's disease). For each disease, the case samples have been ascertained from sites widely distributed across Great Britain, allowing us to obtain considerable efficiencies by comparing each of these case populations to a common set of 3,000 nationally-ascertained controls also from England, Scotland and Wales. These controls come from two sources: 1,500 are representative samples from the 1958 British Birth Cohort and 1,500 are blood donors recruited by the three national UK Blood Services. One of the questions that the WTCCC study has addressed relates to the relative merits of these alternative strategies for the generation of representative population cohorts. Genotyping for this main Case Control study was conducted by Affymetrix using the (commercial) Affymetrix 500K chip. As part of this study a total of 17,000 samples were typed for 500,000 SNPs. There are two additional components to the study. First, the WTCCC award is part-funding a study of host resistance to infectious diseases in African populations. The same approach has been used to type 2,000 cases of tuberculosis (TB) and 2,000 cases of malaria, as well as 2,000 shared controls. As well as addressing diseases of major global significance, and extending WTCCC coverage into the area of infectious disease, the inclusion of samples of African origin has obvious benefits with respect to methodological aspects of genome-wide association analysis. Second, the WTCCC has, for four additional diseases (autoimmune thyroid disease, breast cancer, ankylosing spondylitis, multiple sclerosis), completed an analysis of 15,000 SNPs designed to represent a large proportion of the known non-synonymous coding SNPs across the genome. This analysis has been performed at the WTSI using a custom Infinium chip (Illumina). Data release The genotypic data of the control samples (1958 British Birth Cohort and UK Blood Service) and from seven diseases analyzed in the main study are now available to qualified researchers. Summary genotype statistics for these collections are available directly from the website. Access to the individual-level genotype data and summary genotype statistics is by application to the Consortium Data Access Committee (CDAC) and approval subject to a Data Access Agreement. WTCCC2: A further round of GWA studies were funded in April 2008. These include 15 WTCCC-collaborative studies and 12 independent studies be supported totaling approximately 120,000 samples. Many of the studies represent major international collaborative networks that have together assembled large sample collections. WTCCC2 will perform genome-wide association studies in 13 disease conditions: Ankylosing spondylitis, Barrett's oesophagus and oesophageal adenocarcinoma, glaucoma, ischaemic stroke, multiple sclerosis, pre-eclampsia, Parkinson's disease, psychosis endophenotypes, psoriasis, schizophrenia, ulcerative colitis and visceral leishmaniasis. WTCCC2 will also investigate the genetics of reading and mathematics abilities in children and the pharmacogenomics of statin response. Over 60,000 samples will be analyzed using either the Affymetrix v6.0 chip or the Illumina 660K chip. The WTCCC2 will also genotype 3,000 controls each from the 1958 British Birth cohort and the UK Blood Service control group, and the 6,000 controls will be genotyped on both the Affymetrix v6.0 and Illumina 1.2M chips. WTCCC3: The Wellcome Trust has provided support for a further round of GWA studies in January 2009. These include 5 WTCCC-collaborative studies to be carried out in WTCCC3 and 5 independent studies, across a range of diseases. Many of the studies represent major international collaborative networks that have together assembled large sample collections. WTCCC3 will perform genome-wide association studies in the following 4 disease conditions: primary biliary cirrhosis, anorexia nervosa, pre-eclampsia in UK subjects, and the interactions between donor and recipient DNA related to early and late renal transplant dysfunction. The WTCCC3 will also carry out a pilot in a study of the genetics of host control of HIV-1 infection. Over 40,000 samples will be analyzed using the Illumina 660K chip. The WTCCC3 will utilize the 6,000 control genotypes generated by the WTCCC2. | gene, genomic, genetics, microarray, genome-wide association study, snp, genome-wide association, blood, dna, genotype, variation, genome, sequence variant, copy number variation, genetic variation, phenotype, disease |
is related to: Psychiatric Genomics Consortium has parent organization: Wellcome Trust Sanger Institute; Hinxton; United Kingdom |
Bipolar disorder, Coronary artery disease, Crohn's disease, Rheumatoid arthritis, Type 1 diabetes, Type 2 diabetes, Hypertension, Control, Multiple sclerosis, Breast cancer, Ankylosing spondylitis, Autoimmune thyroid disease, Malaria, Tuberculosis, Inflammatory bowel disease, Barrett's esophagus, Esophageal adenocarcinoma, Glaucoma, Ischemic stroke, Pre-eclampsia, Parkinson's disease, Psychosis endophenotypes, Psoriasis, Schizophrenia, Ulcerative colitis, Visceral leishmaniasis, Primary biliary cirrhosis, Anorexia nervosa, Human immunodeficiency virus, Renal transplant dysfunction, Diabetes | Wellcome Trust ; Bill and Melinda Gates Foundation ; Wellcome Trust Sanger Institute; Hinxton; United Kingdom |
PMID:17554300 | Access to summary data and individual-level genotype data is available by application to the Wellcome Trust Case Control Consortium Data Access Committee. Access to data will be granted to qualified investigators for appropriate use. | nif-0000-10551 | SCR_001973 | Wellcome Trust Case-Control Consortium (WTCCC) | 2026-02-14 02:00:12 | 213 | ||||
|
Criminal Justice Drug Abuse Treatment Studies Resource Report Resource Website |
Criminal Justice Drug Abuse Treatment Studies (RRID:SCR_006996) | CJ-DATS, CJDATS | knowledge environment | A cooperative research program to explore the issues related to the complex system of offender treatment services. Nine research centers and a Coordinating Center were created in partnership with researchers, criminal justice professionals, and drug abuse treatment practitioners to form a national research infrastructure. The establishment of CJ-DATS is an outstanding example of cooperation among Federal agencies with the research community... We need to understand how to provide better drug treatment services for criminal justice offenders to alter their drug use and criminal behavior. - Dr. Nora Volkow, Director of NIDA. CJ-DATS PHASE I In 2002, NIDA launched the National Criminal Justice����������Drug Abuse Treatment Studies (CJ-DATS). CJ-DATS is a multisite research program aimed at improving the treatment of offenders with drug use disorders and integrating criminal justice and public health responses to drug involved offenders. From 2002 through 2008, CJ-DATS researchers from 9 research centers, a coordinating center, and NIDA worked together with federal, state, and local criminal justice partners to develop and test integrated approaches to the treatment of offenders with drug use disorders. The areas that were studied included: * Assessing Offender Problems * Measuring Progress in Treatment and Recovery * Linking Criminal Justice and Drug Abuse Treatment * Adolescent Interventions * HIV and Hepatitis Risk Reduction * Understanding Systems CJ-DATS PHASE II In 2008, CJ-DATS began to focus on the problems of implementing research-based practices drug treatment practices. This research concerns the organizational and systems processes involved in implementing valid, evidence-based practices to reduce drug use and drug-related recidivism for individuals in the criminal justice system. 12 CJ-DATS Research Centers are conducting implementation research in three primary domains: * Research to improve the implementation of evidence-based assessment processes for offenders with drug problems * Implementing effective treatment for drug-involved offenders * Implementing evidence-based interventions to improve an HIV continuum-of-care for offenders | drug, aids, criminal, health, hiv, offender, treatment, justice, drug abuse, drug treatment service, criminal justice offender, drug use, criminal behavior, recovery, adolescent, intervention, hepatitis |
is related to: NIDA Networking Project: Facilitating information exchange and research collaboration has parent organization: National Institute on Drug Abuse |
Drug use disorder | NIDA | nif-0000-10202 | SCR_006996 | Criminal Justice-Drug Abuse Treatment Studies | 2026-02-14 02:01:16 | 0 | ||||||
|
Diabetes Autoantibody Standardization Program Resource Report Resource Website 10+ mentions |
Diabetes Autoantibody Standardization Program (RRID:SCR_006929) | DASP | knowledge environment | Program that develops materials and methods to improve measurements of autoantibodies that are predictive of type 1 diabetes. These are the most sensitive and meaningful measures for predicting this disease. Historically, autoantibody measures have been variable among laboratories; therefore, this program, in collaboration with the Immunology of Diabetes Society, was established. The goals of DASP are to improve laboratory methods, evaluate laboratory performance, support the development of sensitive and specific measurement technologies, and develop reference methods. Currently, 48 key laboratories from 19 countries participate in DASP. | autoantibody, quality assurance, standardization, standard, laboratory method, laboratory performance, measurement, method |
is related to: NIDDK Information Network (dkNET) has parent organization: Centers for Disease Control and Prevention |
Type 1 diabetes, Diabetes | PMID:12716742 | nlx_152868 | http://www.idsoc.org/committees/antibody/dasphome.html | SCR_006929 | Diabetes Autoantibody Standardization Program (DASP) | 2026-02-14 02:01:24 | 14 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant 2U24DK097771-09.
Email: info_at_ dknet.org
